STOCK TITAN

AgeX Therapeutics Inc - AGE STOCK NEWS

Welcome to our dedicated news page for AgeX Therapeutics (Ticker: AGE), a resource for investors and traders seeking the latest updates and insights on AgeX Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AgeX Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AgeX Therapeutics's position in the market.

Rhea-AI Summary
AgeX Therapeutics, Inc. reported financial results for Q4 and full year 2023, including recent highlights like merger approval with Serina Therapeutics, Inc. and increase in line of credit. The company eliminated $36 million of indebtedness by issuing preferred stock, with cash totaling $0.3 million as of December 31, 2023. Operating expenses increased, with net loss of $14.8 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
-
Rhea-AI Summary
AgeX Therapeutics, Inc. (AGE) reported Q3 financial results, including $36M of debt converted into preferred stock, a merger agreement with Serina Therapeutics, and an increase in line of credit by $4.4M. The company also issued shares of preferred stock to eliminate $36M of indebtedness, while the cash, cash equivalents, and restricted cash totaled $0.4M as of September 30, 2023. Operating expenses for Q3 2023 were $2.4M, with a net loss of $5.4M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
-
Rhea-AI Summary
Serina Therapeutics and AgeX Therapeutics announce merger to focus on developing therapeutics based on Serina's proprietary POZ Platform™ delivery technology. Lead program will be SER-252 for advanced Parkinson's Disease. Focus on expanding partnerships in immunology, cancer Rx, and gene therapy fields.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.65%
Tags
-
Rhea-AI Summary
AgeX Therapeutics cancels $36 million of debt in exchange for preferred stock, meeting NYSE listing requirements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
none
-
Rhea-AI Summary
AgeX Therapeutics, Inc. (NYSE American: AGE) entered into an Exchange Agreement with Juvenescence Limited, issuing 211,600 shares of Series A Preferred Stock and 148,400 shares of Series B Preferred Stock in exchange for the cancellation of $36 Million of indebtedness. The purpose is to bring AgeX common stock back into compliance with NYSE American listing requirements. The exchange would increase AgeX's stockholders equity to approximately $16 Million from a deficit of $20 Million. The exchange of indebtedness for Preferred Stock is expected to occur on or around July 25, 2023, subject to NYSE American approval and filing of necessary documents. The Preferred Stock is not entitled to receive cash or other dividends, and has limited voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AgeX Therapeutics Inc

NYSE:AGE

AGE Rankings

AGE Stock Data

27.76M
2.45M
0.01%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Alameda

About AGE

agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha